Openbookopenbook
Openbook
BIS
-2.17 · -19.78%
$8.81 · NASDAQ

ProShares UltraShort Nasdaq Biotechnology (BIS) ETF Analysis | Trading--Inverse Equity

ProShares · United States
AUM:$2.5M
#– of – in Trading--Inverse Equity ETFs

Educational tool only – Figures are based on historical data, holdings and expense metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Market Performance

Down 49.0% over the past year, indicating meaningful price weakness.

Cost Efficiency

Ongoing charge of 0.95% — above average for this category.

What is BIS?

The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies.

Performance Highlights

Returns (%)
Cost & Yield (%)

Investment Breakdown

Negative 12-Month Return
BIS returned -49.0% over the past year, reflecting recent market conditions.
Higher Cost Profile
Expense ratio of 0.95% is above average. Verify whether the strategy justifies the cost.
Moderate Concentration
Top 10 holdings make up 48.0% of the ETF — a moderate level of name concentration.
ETF Information
AUM$2.5M
Expense Ratio0.95%
Dividend Yield4.92%
Holdings104
Inception DateApr 2010
DomicileUnited States
DistributionNA
Index–
ProviderProShares
Beta-1.45
CategoryTrading--Inverse Equity
CurrencyUSD
Portfolio Impact

How would BIS affect your portfolio?

Sign in to see exactly what adding this ETF changes — sector exposure, yield, diversification, volatility. Real numbers from your actual holdings.

Sign in
Example preview
6168
+7 points · better diversified

Chart Tools

My Portfolio

Sign in to overlay your portfolio on the chart.

Sign in
Compare Equity
Uses ISF.L (iShares FTSE 100 ETF)
Indicators

Performance Metrics

Historical returns

6M
+35.4%
1Y
-19.0%
3Y
-38.8%
5Y
-24.9%
OpenBook InsightIf you had invested £10,000 in BIS 5 years ago, it would have fallen to £7,506 — a loss of £2,494.

Annual Returns

Calendar year performance

BIS delivered positive returns in 2 of the last 5 calendar years.
YearBIS
2026 YTD+20.1%
2025-45.4%
2024+9.1%
2023-8.2%
2022-0.9%
CAGR 4yr-14.2%
2/5 positive yearsAvg return: -5.1%Worst year: -45.4% (2025)

Technical Analysis Summary

Automated insights from historical price action and indicators

Technical Regime: MIXED
Trend Strength
33%
Negative
Volatility
54.1%
Very High
Momentum
-19.4%
30-day change
Support Level
10.53
Key floor
Key Insights
  • Momentum is downward with a 19.4% move over 30 days.
  • Elevated volatility indicates higher short-term price variability and risk.
  • Monitor key support and resistance levels as part of broader risk assessment.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.